Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : KN-002
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Kinaset Therapeutics Shares Positive Data from Phase 1b KN-002 Study at ATS 2024
Details : KN-002 is a pan-JAK inhibitor formulated as a dry powder for delivery via the non-invasive oral inhalation. It is being evaluated in a Phase 1 for mild to severe asthma and those with COPD.
Brand Name : KN-002
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 21, 2024
Lead Product(s) : KN-002
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : VR588
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Vectura Ltd
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : This agreement provides an opportunity for Vectura to realise value from its historical research and investment in VR588, whilst expanding its CDMO development services portfolio by supporting the product's further development with Kinaset.
Brand Name : VR588
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 30, 2020
Lead Product(s) : VR588
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Vectura Ltd
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?
Reset All
